Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MYCN gene encodes the N-MYC protein, a transcription factor belonging to the Myc family. It is crucial for embryonic development, regulating cell growth, division, differentiation, and apoptosis. MYCN is an oncogene, and its amplification or overexpression is associated with several cancers, most notably neuroblastoma. Mutations or deletions in MYCN are also associated with developmental disorders like Feingold Syndrome Type 1.
N-MYC acts as a transcription factor regulating the expression of target genes involved in cell proliferation, apoptosis, and differentiation. It dimerizes with other bHLH proteins to bind DNA and activate transcription. The antisense RNA transcript (MYCNOS or NCYM) stabilizes N-MYC protein levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYCN proto-oncogene (N-Myc).